Key points are not available for this paper at this time.
This study uses SSR Health data on drug list prices and estimated net prices after manufacturer discounts to evaluate trends in prices for newly marketed brand-name prescription drugs in the US from 2008 to 2021.
Rome et al. (Tue,) studied this question.